Kilitch Drugs (India) share news, announcements and annual reports
NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap
Kilitch Drugs (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Sep 2010 on NSE
Last close ₹201.32down ₹7.82 (3.74%)BSE ₹201.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.14.
30 Oct: open ₹211.45, high ₹212.24, low ₹200.25
52-week range of traded prices to 30 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹704 Cr1,776th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 23.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.52
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,67341.3% delivered
Kilitch Drugs (India) routine notices
124 filed, newest first. Page 3 of 3.
Dec 2021
Sep 2021
Jun 2021
Apr 2021
29 Apr · Routine
Mar 2021
Jan 2021
Dec 2020
Sep 2020
8 Sep · Routine
Aug 2020
29 Aug · Routine
Jun 2020
Mar 2020
Dec 2019
Oct 2019
Jul 2019
Apr 2019
May 2016
Feb 2016
Nov 2015
Aug 2015
May 2015
Feb 2015
Nov 2014
3 Nov · Routine
As per the Company's Code of Conduct for Prohibition of Insider Trading, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the Company will be closed for the purpose of declaration of financial results of the Company for the quarter ended September 30, 2014 from November 3, 2014 to November 15, 2014. Accordingly, all the Designated Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window.